India's Number #1 Calcium Channel Blocker Brand*

cilacar

About CILACAR 5/10/20 mg tablets

CILACAR (Cilnidipine) is a 4th Generation Dihydropyridine (DHP) calcium channel blocker. It is used for the treatment of Hypertension.

Cilacar is marketed by J. B. Chemicals & Pharmaceuticals Ltd. and comes in three doses namely CILACAR 5 mg, CILACAR 10 mg, CILACAR 20mg.

Cilnidipine is a 4th Generation Dihydropyridine (DHP) calcium antagonist with a slow onset and long duration of action. Calcium antagonist inhibit influx of extracellular calcium ions into the cells, resulting in decreased vascular smooth muscle tone and vasodilation, leading to a reduction in blood pressure.

In human studies, Cilnidipine had weak inotropic effects and suppressed cardiac sympathetic overactivity. Therefore, it may decrease the risk and mortality from long term cardiovascular complications. Once-daily Cilnidipine was associated with less reflex tachycardia and had fewer effects on the autonomic nervous system in hypertensive patients (see Product Leaflet).

Reduces Arterial Stiffness and Lowers Central Aortic BP1

As efficacious as Amlodipine with better tolerability in hypertensive patients3

graph1

Significantly reduces albuminuria in diabetic
hypertensives4

graph2

Offers Smooth Reduction of Blood Pressure with Less Chances of Hypotension5,6

As efficacious as Amlodipine with better tolerability in Patients with hypertension7

Reduction inHR by 3 beats/min8

Minimal incidence of pedal oedema9

Reduction in uric acid8

Safe and Effective in Reducing low-grade Albuminuria in Hypertension CKD Patients10

Equal efficacy compared to Amlodipine in BP reduction11

graph1

Suppresses glomerular
hypertension12

hypertension

Effective Management of Hypertension with Elevated HR

Sustained BP Control With Neuroprotective Effects

BP variability is least with Cilnidipine compared to other CCBs17

Regresses c-IMT & reduces IAD in post - stroke hypertensive patients18

Overview

Name of Product : Cilacar 5mg/10mg/20mg
Manufacturer : J.B. Chemicals & Pharmaceuticals Ltd.
Medicine composition: Cilnidipine
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Tablets

Download the Product Leaflet, to see the details on Overview of Cilacar.

Indications of Cilacar

Cilnidipine is used for the treatment of mild to moderate hypertension.

Download the Product Leaflet, to see the details on Indications of Cilacar.

Cilnidipine Dose and Method of Administration

The recommended adult oral dosage of Cilnidipine is 5-10 mg once daily. The dosage can be increased up to 20 mg, if needed. Starting dose 5 to 10 mg per day depending on individual case. Maintaining dose- physician will titrate the dose as per patient’s symptoms.

Download the Product Leaflet, to see the details on Dose and Method of Administration of Cilacar.

Contraindications

Advanced aortic stenosis, Hypersensitivity to Cilnidipine or other calcium channel antagonists.

Download the Product Leaflet, to see the details on Contraindications of Cilacar.

Warnings and Precautions

Cilnidipine should be used carefully in patients with Angina, Chronic renal insufficiency, Congestive heart failure, Hypotension, Liver dysfunction, or elevated liver enzymes and Peripheral edema (confounding physical findings in congestive failure).

Download the Product Leaflet, to see the details on Warnings and Precautions of Cilacar.

Cilnidipine Drug Interactions

Cilnidipine can interact with aldesleukin, quinidine, phenytoin, rifampicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drug.

Download the Product Leaflet, to see the detailed drug interactions.

Adverse Reactions

Dizziness, headache, peripheral edema, flushing, rash and gingival hyperplasia are the most common adverse events seen with the dihydropyridine derivative calcium channel antagonists. Headache, Flushing was reported in 3.7 & 4.5% of 764 subjects receiving cilnidipine respectively.

Download the Product Leaflet,to see the details on adverse reactions of Cilacar.

Cilnidipine Side effects/ Overdose

Download the Product Leaflet, to see the details on Undesirable Side effects/ Overdose of Cilacar.

Pharmacodynamic and Pharmacokinetic Properties

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Cilacar.

Contact us for further information

References

* Data on file, 1. Journal of Clinical Diagnostic Reasearch 2015 Nov, Vol-9(11):FC13-FC16. 2. J Cardiovasc Pharmacol 2004 Jan;43(1):68-73. 3. J Adv Pharm Technol Res. 2015 Apr-Jun; 6(2): 81-85. 4. Astan J Pharm Clin Res 2021; 14(1): 144-146. 5. Int J Pharm Sci Res. 3(12); 5044-5055. 6. Diálisis y Trasplante 2013; 34(1): 2-6 (DOI: 10.1016/j.dialis.2012.04.001) 7. Sch. J. App. Med. Sci., 2016; 4(8C):2884-2894. 8. Cardiol Res. 2016;7(5):167-172. 9. J Adv Pharm Technol Res. Apr-Jun;2015 6(2): 81-85. 10. Dialisis y Trasplante Volume 34, Issue 1, January-March 2013, Pages 2-6. 11. Global Journal of Research Analysis 2020; 9(1): 9-11. 12. Kidney International (2007) 72,1543-1549. 13. J Clin Hypertens (greenwich). 2013 Feb;15(2):133-42. 14. Cardiol Res. 2016;7(5):167-172. 15. Journal of Clinical and Diagnostic Research.2015 Nov,Vol-9(11):FC13-FC16. 16. Heart Vessel (2013) 28: 480-489. 17. J Adv Pharm Technol Res. 2015 Apr-Jun; 6(2): 81–85. 18. J Stroke Cerebrovasc Dis. 2015 Aug;24(8):1848-54. 19. J Atheroscler Thromb, 2018; 25: 490-504.
X
Advertisement